Latest Breaking News On - Manderson cancer - Page 6 : comparemela.com

Cervical cancer rates rising in low-income U S counties

Women in low-income areas of the U.S. face a stark rise in cervical cancer incidence and mortality, according to a new study led by researchers from The Univers

Ashish deshmukhTrisha amboreeJane montealegreUniversity of texasInternational journal of cancerNational cancer instituteHealth disparitiesAnderson cancer centerUniversity of south carolina hollings cancer centerNational institute on minority healthManderson cancerInternational journalCancer controlMedical universitySouth carolina hollings cancer centerNational institute

Cord blood-derived CAR NK cell therapy targeting CD19 shows promise for treating patients with B-cell malignancies

Researchers from The University of Texas MD Anderson Cancer Center reported promising results in a Phase I/II trial of 37 patients with relapsed or refractory B-cell malignancies who were treated with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting CD19.

United statesKaty rezvaniSally cooper murrayResearch institute of texasUniversity of texas md anderson cancer centerNational institutes of healthCancer researchMd anderson moon shots programManderson cancerCancer centerNature medicineStem cell transplantationNew england journalSally cooper murray endowed chairNational institutesCancer prevention

Long-term findings from CAR NK cell therapy trial revealed

Long-term findings from CAR NK cell therapy trial revealed
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

United statesKaty rezvaniNature medicineStem cell transplantationCellular therapyManderson cancer

Researchers find powerful combo weapon against aggressive lymphoma

The targeted therapy combination of ibrutinib and venetoclax significantly improved progression-free survival (PFS) and achieved an overall remission rate in 82% of patients with relapsed/refractory mantle cell lymphoma (MCL), according to researchers at The University of Texas MD Anderson Cancer Center. Results from the Phase III SYMPATICO trial were presented at the 2023 American Society of Hematology (ASH) Annual Meeting.

United statesMichael wangAmerican society of hematologyUniversity of texas md anderson cancer centerManderson cancerMantle cell lymphoma

Targeted therapy reduces markers of disease burden, improves symptoms for patients with nonadvanced system mastocytosis

The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with a rare blood disorder called nonadvanced system mastocytosis, according to results of the Phase II SUMMIT trial reported by researchers at The University of Texas MD Anderson Cancer Center.

United statesIonis incytePrithviraj boseUniversity of texas md anderson cancer centerBristol myers squibbAmerican society of hematologyManderson cancerAnnual meetingCogent biosciencesBlood disorderBone marrowCentral nervous systemMast cellNervous system